← Back to Clinical Trials
Recruiting NCT07399964

Effects of CBT-I on Impulsivity and Risk Taking in Youths With Insomnia

Trial Parameters

Condition Insomnia
Sponsor The University of Hong Kong
Study Type INTERVENTIONAL
Phase N/A
Enrollment 124
Sex ALL
Min Age 12 Years
Max Age 24 Years
Start Date 2024-06-19
Completion 2026-12-01
Interventions
Cognitive Behavioural Therapy for InsomniaHealth-related Psychoeducation

Brief Summary

Insomnia is prevalent in adolescents. Impulsive behaviours and excessive risk-taking have been linked to the manifestation of psychopathology in youths. Previous research based on behavioural and neurophysiological measures has found that individuals with insomnia demonstrated impaired inhibitory control, which is associated with detrimental outcomes such as substance abuse and self-harm. Existing evidence has shown some positive effects of cognitive behavioural therapy for insomnia (CBT-I) on insomnia symptoms and daytime functioning in youths. Given the link between insomnia and impulsivity reported in previous research, and sleep as a highly modifiable factor, we are conducting this randomised controlled trial to examine the impact of CBT-I in improving impulsivity and risk-taking in youth with insomnia.

Eligibility Criteria

Inclusion Criteria: * Chinese aged 12-24 years old * Written informed consent of participation in the study is given by the participant and his/her parent or guardian (for those aged under 18) * Willing to comply with the study protocol * Meeting the DSM-V diagnostic criteria of insomnia disorder and with a score on Insomnia Severity Index (ISI) \>= 9 (suggested cut-off for adolescents) Exclusion Criteria: * A current diagnosis of substance abuse or dependence; a current or past history of manic or hypomanic episode, schizophrenia spectrum disorders, neurodevelopmental disorders, organic mental disorders, or intellectual disabilities * Having a prominent medical condition known to interfere with sleep continuity and quality (e.g. eczema, gastro-oesophageal reflux disease) * Having a clinically diagnosed sleep disorder (other than insomnia disorder) that may potentially contribute to a disruption in sleep continuity and quality, such as narcolepsy, sleep-disordered breathing, and restle

Related Trials